CRISPR Therapeutics AG: general counsel Kasinger James R. sold 1,990 shares

What happened

• The filing shows Kasinger James R., general counsel, exercised options for 1,990 common shares at $13.62 per share (total cost $27,104) and sold 1,990 common shares on Oct 6, 2026, at a weighted average price of $60.04 per share (total proceeds $119,481). The filing also reports a derivative disposition of 1,990 shares at $0.00.

Key details

• Transaction date: Oct 6, 2026.
• Prices and amounts: exercised 1,990 shares at $13.62 (acquired $27,104); sold 1,990 shares at weighted average $60.04 (disposed $119,481); derivative disposition 1,990 shares at $0.00.
• Shares owned after the transaction: not reported in this Form 4.
• Footnotes from the filing:
  • F1: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted May 6, 2026.
  • F2: The $60.04 price is a weighted average; shares were sold in multiple transactions at prices ranging from $60.00 to $60.08. The reporting person will provide a breakdown on request.
  • F3: The option was granted May 31, 2017 with respect to 123,000 common shares; 25% vested May 31, 2018 and the remaining 75% vested monthly over 36 months.
• Filing date: Oct 8, 2026. No late filing is indicated in the report.

Why it may matter

• The filing shows an option exercise and immediate sale of the same number of shares on the same day, consistent with a cashless exercise and sale.
• The sale was executed under a Rule 10b5-1 plan per the filing.
• This filing does not show why the insider traded or why the company acted.